| Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
| 2021 | Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective | YC Hsu; CH Tseng; YT Huang ; HI Yang | Seminars in liver disease 41(03), 285-297 | | | |
| 2018 | Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B | YC Hsu; TCF Yip; HJ Ho; VWS Wang; YT Huang ; HB El-Serag; TY Lee; MS Wu; JT Lin; GLH Wong; CY Ying | JOURNAL OF HEPATOLOGY 69(2), 278-285 | | | |
| 2020 | Editorial: risk assessment for chronic hepatitis B patients in the immune tolerant phase—both definition and selection matter | YC Hsu; YT Huang | Alimentary Pharmacology & Therapeutics 52(1), 213-214 | | | |
| 2022 | Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort | YC Hsu; DW Jun; CY Peng; ML Yeh; H Trinh; GL Wong; SE Kim; CH Chen; H Oh; CH Lin; L Trinh; VW Wong; E Yoon; SB Ahn; D Huang; YK Cho; JY Jeong; SW Jeong; HS Kim; Q Xiw; L Liu; M Riveiro-Barciela; PC Tsai; EV Accarino; H Toyoda; M Enomoto; C Preda; S Marciano; J Hoang; CF Huang; R Kozuka; S Yasuda; D Istratescu; DH Lee; JY Su; YT Huang ; JF Huang; CY Dai; WL Chuang; MF Yuen; A Gadano; R Cheung; SG Lim; M Buti; ML Yu; MH Nguyen | HEPATOLOGY INTERNATIONAL 16, 1297-1307 | | | |
| 2021 | Fibrosis in Patients with Chronic Hepatitis B and Minimally Raised ALT during Tenofovir Therapy – Authors’ reply | YC Hsu; YT Huang ; JT Lin | LANCET INFECTIOUS DISEASES 21(7), 911 | | | |
| 2022 | Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations With Implications on Host Gene Dysregulation | YC Hsu; V Suri; MH Nguyen; YT Huang ; CY Chen; IW Chen; CH Tseng; CY Wu; JT Lin; D Pan; A Gaggar; Ondrej Podlaha | Gastroenterology 162(4), 1160-1170.e1 | | | |
| 2019 | Mac-2-Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients with Chronic Hepatitis B or C Infection | T Jun; YC Hsu; S Ogawa; YT Huang ; ML Yeh; CH Tseng; CF Huang; CM Tai; CY Dai; JF Huang; WL Chuang; ML Yu; Y Tanaka; MH Nguyen | Hepatology Communication 3(4), 493-503 | | | |
| 2021 | Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial | YC Hsu; CY Chen; IW Chang; CY Chang; CY Wu; TY Lee; MS Wu; MJ Bair; JJ Chen; CC Chen; CH Tseng; CM Tai; YT Huang ; WH Ku; LR Mo; JT Lin | LANCET INFECTIOUS DISEASES 21(6), 823-833 | | | |
| 2018 | Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti‐viral therapy in patients with chronic hepatitis B | YC Hsu; T Jun; YT Huang ; ML Yeh; CL Lee; SH Cho; JT Lin; ML Yu; MH Nguyen; Y Tanaka | ALIMENTARY PHARMACOLOGY & THERAPEUTICS 48(10), 1128-1137 | | | |
| 2020 | Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B | YC Hsu; GLH Wong; CH Chen; CY Peng; ML Yeh; KS Cheung; H Toyoda; CF Huang; H Trinh; Q Xie; M Enomoto; L Liu; S Yasuda; Y Tanaka; R Kozuka; PC Tsai; YT Huang ; C Wong; R Huang; TY Jang; J Hoang; HI Yang ; J Li; DH Lee; H Takahashi; JQ Zhang; E Ogawa; C Zhao; C Liu; N Furusyo; Y Eguchi; C Wong; C Wu; T Kumada; MF Yuen; ML Yu; M Nguyen | American Journal of Gastroenterology 115(2), 271-280 | | | |
